Antisense oligonucleotides: New tools for physiology

News in Physiological Sciences

Volumn 12, Issue 3, 1997, Pages 99-105

  Phillips, M Ian ^a   Gyurko, Robert ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0031490476     PISSN: 08861714     EISSN: None     Source Type: Journal    
DOI: 10.1152/physiologyonline.1997.12.3.99     Document Type: Article

References (15)

1. 1 receptor. Regul. Pept. 59: 171-182, 1995.
2. Burgess, T. L., E. F. Fisher, S. L. Ross, J. V. Bready, Y.-X. Qian, L. A. Bayewitch, A. M. Cohen, C. J. Herrera, S. S.-F. Hu, T. B. Kramer, F. D. Lott, F. H. Martin, G. F. Pierce, L. Simonet, and C. L. Farrell. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. USA 92: 4051-4055, 1995.
3. Crooke, S. T. Progress toward oligonucleotide therapeutics; pharmacodynamic properties. FASEB J. 7: 533-539, 1993.
4. 1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul. Pept. 49: 167-174, 1993.
5. 1 receptor mRNA antisense oligonucleotide inhibits central angiotensin induced thirst and vasopressin. Regul. Pept. 54: 543-551, 1994.
6. Morishita, R., G. H. Gibbons, K. E. Ellison, M. Nakajima, L. Zhang, Y. Kaneda, T. Ogihara, and V. J. Dzau. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad Sci. USA 90: 8474-8478, 1993.
7. Phillips, M. I. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension. Hypertension 29: 177-187, 1997.
8. Phillips, M. I., D. Wielbo, and R. Gyurko. Antisense inhibition of hypertension: a new strategy for reninangiotensin candidate genes. Kidney Int. 46: 1554-1556, 1994.
9. 1 receptor antisense oligonucleotide inhibits the behavioral actions of angiotensin II. J. Neurochem. 62: 2053-2056, 1994.
10. Simons, M., E. R. Edelman, J.-L. DeKeyser, R. Langer, and R. D. Rosenberg. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359: 67-70, 1992.
11. Stein, C. A. Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. Trends Biotechnol. 14: 147-149, 1996.
12. Tomita, N., R. Morishita, J. Higaki, Y. Kaneda, H. Mikami, and T. Ogihara. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotide against rat angiotensinogen. Hypertension 26: 131-136, 1995.
13. Wagner, R. W. The state of the art in antisense research. Nature Med. 1: 1116-1118, 1995.
14. Wahlestedt, C., E. M. Pich, G. F. Koob, F. Yee, and M. Heilig. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 259: 528-531, 1993.
15. Wielbo, D., C. Sernia, R. Gyurko, and M. I. Phillips. Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension 25: 314-329, 1994.